Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...

Vertex stock nose-dived Tuesday after the biotech company said it wouldn't advance its next-generation pain drug into ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $481.56, ...

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...